Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as stavudine extended-release, lamivudine, efavirenz
stavudine, lamivudine, efavirenz · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| stavudine extended-release, lamivudine, efavirenz | DRUG | - |
Inclusion Criteria: * Documented HIV infection * 18 years of age or older and weigh at least 40 kg * Two plasma HIV RNA levels below the limit of quantification (one at least 90 days prior to the screening visit and one within 30 days of the patients baseline visit) * Currently receiving a standard...
Top 18 of 27 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 5 | PHASE3 | VLA15, ATM-AVI, PG4, Prevenar 20 |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE3 | PCV21 |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Stavudine, lamivudine, efavirenz is a once-daily combination antiretroviral regimen being studied for the treatment of HIV-1 infection. It combines three small molecule antivirals in a single daily dosing schedule, and was evaluated in a Phase 3 trial of switching HIV-1 infected adults from a more frequent HAART regimen.
Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY, is the developer of the stavudine, lamivudine, efavirenz combination regimen.
Stavudine, lamivudine, efavirenz reached Phase 3 development. The combination is investigational and is not described as approved. One Phase 3 trial has been completed, and no trials of this regimen are currently active.
Stavudine, lamivudine, efavirenz was studied in one completed Phase 3 trial, NCT00135369, titled Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen. It enrolled 300 adults aged 18 and older in the United States and Puerto Rico.
Yes. Stavudine extended-release, lamivudine, efavirenz is another name for the same combination regimen. Both names refer to the once-daily three-drug HIV-1 treatment developed by Bristol-Myers Squibb.
The Phase 3 trial NCT00135369 was a randomized study with 300 participants, comparing a switch to once-daily dosing against the prior HAART regimen dosed twice daily or more often. It was not double-blind and used an uncontrolled design, and it has been completed.